SPIA
CRSP icon

Steward Partners Investment Advisory’s CRISPR Therapeutics CRSP Stock Holding History

Steward Partners Investment Advisory’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$143K Sell
2,623
-50
-2% -$2.63K ﹤0.01% 2412
2026
Q1 		$127K Sell
2,673
-380
-12% -$20K ﹤0.01% 2247
2025
Q4 		$160K Buy
3,053
+292
+11% +$17.5K ﹤0.01% 2039
2025
Q3 		$179K Buy
2,761
+769
+39% +$44.1K ﹤0.01% 1928
2025
Q2 		$96.9K Buy
1,992
+552
+38% +$21.4K ﹤0.01% 2134
2025
Q1 		$49K Buy
1,440
+579
+67% +$24.5K ﹤0.01% 2389
2024
Q4 		$33.9K Sell
861
-87
-9% -$4.11K ﹤0.01% 2539
2024
Q3 		$44.5K Sell
948
-191
-17% -$9.69K ﹤0.01% 2287
2024
Q2 		$61.5K Sell
1,139
-403
-26% -$23.3K ﹤0.01% 2001
2024
Q1 		$105K Sell
1,542
-460
-23% -$32.9K ﹤0.01% 1743
2023
Q4 		$125K Buy
2,002
+18
+0.9% +$995 ﹤0.01% 1582
2023
Q3 		$90.1K Buy
1,984
+31
+2% +$1.6K ﹤0.01% 1631
2023
Q2 		$110K Sell
1,953
-35
-2% -$1.99K ﹤0.01% 1546
2023
Q1 		$89.9K Sell
1,988
-20
-1% -$971 ﹤0.01% 1631
2022
Q4 		$81.6K Buy
2,008
+95
+5% +$5.04K ﹤0.01% 1626
2022
Q3 		$125K Sell
1,913
-31
-2% -$2.25K ﹤0.01% 1401
2022
Q2 		$118K Buy
1,944
+148
+8% +$8.7K ﹤0.01% 1432
2022
Q1 		$113K Buy
1,796
+1,093
+155% +$68.6K ﹤0.01% 1556
2021
Q4 		$53K Sell
703
-348
-33% -$30.4K ﹤0.01% 1875
2021
Q3 		$118K Sell
1,051
-719
-41% -$90.3K ﹤0.01% 1480
2021
Q2 		$287K Sell
1,770
-2,384
-57% -$290K ﹤0.01% 1212
2021
Q1 		$506K Buy
4,154
+3,237
+353% +$489K 0.01% 884
2020
Q4 		$140K Buy
917
+544
+146% +$64.3K ﹤0.01% 1219
2020
Q3 		$31K Buy
373
+73
+24% +$6.47K ﹤0.01% 1708
2020
Q2 		$22K Hold
300
– – ﹤0.01% 1728
2020
Q1 		$12K Hold
300
– – ﹤0.01% 1780
2019
Q4 		$18K Hold
300
– – ﹤0.01% 1800
2019
Q3 		$12K Hold
300
– – ﹤0.01% 1902
2019
Q2 		$14K Buy
+300
New +$12K ﹤0.01% 1829
2018
Q4 		– Sell
-300
Closed -$13K – 1029
2018
Q3 		$13K Buy
300
+200
+200% +$10.5K ﹤0.01% 1756
2018
Q2 		$6K Hold
100
– – ﹤0.01% 1920
2018
Q1 		$4K Buy
+100
New +$4.13K ﹤0.01% 1837

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Steward Partners Investment Advisory's CRSP Position: Q2 2026 in Review

Steward Partners Investment Advisory reduced its CRISPR Therapeutics (CRSP) stake by 1.9% in Q2 2026, selling an estimated $2.63K and leaving 2,623 shares worth $143K. The position accounts for ﹤0.01% of the portfolio, ranked #2412.

Steward Partners Investment Advisory first reported a position in CRSP in Q1 2018 and has held it in 32 quarters since. The position peaked at $506K in Q1 2021. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Steward Partners Investment Advisory held 2,623 shares of CRISPR Therapeutics worth $143K as of Q2 2026.
  • Steward Partners Investment Advisory sold 50 CRISPR Therapeutics shares in Q2 2026, an estimated $2.63K.
  • CRISPR Therapeutics made up ﹤0.01% of Steward Partners Investment Advisory's portfolio in Q2 2026, its #2412 holding.
  • Steward Partners Investment Advisory first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 32 quarters since.
  • Steward Partners Investment Advisory's CRISPR Therapeutics position peaked at $506K in Q1 2021.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Steward Partners Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.